The UCL Institute of Biomedical Engineering (IBME) has high ambitions – no less than to be one of the world’s best university-based proponents of medical technologies R&D, and of its successful translation into products of significant patient benefit and real commercial value. In a 2011 survey commissioned by the NIHR, UCL Biomedical Engineering led the UK in the percentage share of most highly cited publications, at 13%.
IBME is a bridge between six biomedical, engineering, life and physical science faculties, and the hospitals, in the UCL estate. It aims to establish a cross-faculty consortium for the promotion of innovation and translational research in medical technologies viz. non-pharmaceutical products that are used to diagnose, monitor and treat diseases or conditions that affect humans.
Alongside a goal of supporting translational activities, including direct support of PIs via site miners, transaction experts and venture facilitators, will be bottom-up support of postgraduates through an Enterprise Academy and taught courses on MedTech Entrepreneurship.